Differential roles of Hath1, MUC2 and P27Kip1 in relation with gamma-secretase inhibition in human colonic carcinomas: a translational study

PLoS One. 2013;8(2):e55904. doi: 10.1371/journal.pone.0055904. Epub 2013 Feb 11.

Abstract

Hath1, a bHLH transcription factor negatively regulated by the γ-secretase-dependent Notch pathway, is required for intestinal secretory cell differentiation. Our aim was fourfold: 1) determine whether Hath1 is able to alter the phenotype of colon cancer cells that are committed to a differentiated phenotype, 2) determine whether the Hath1-dependent alteration of differentiation is coupled to a restriction of anchorage-dependent growth, 3) decipher the respective roles of three putative tumor suppressor genes Hath1, MUC2 and P27kip1 in this coupling and, 4) examine how our findings translate to primary tumors. Human colon carcinoma cell lines that differentiate along a mucin secreting (MUC2/MUC5AC) and/or enterocytic (DPPIV) lineages were maintained on inserts with or without a γ-secretase inhibitor (DBZ). Then the cells were detached and their ability to survive/proliferate in the absence of substratum was assessed. γ-secretase inhibition led to a Hath1-mediated preferential induction of MUC2 over MUC5AC, without DPPIV modification, in association with a decrease in anchorage-independent growth. While P27kip1 silencing relieved the cells from the Hath1-induced decrease of anchorage-independent growth, MUC2 silencing did not modify this parameter. Hath1 ectopic expression in the Hath1 negative enterocytic Caco2 cells led to a decreased anchorage-independent growth in a P27kip1-independent manner. In cultured primary human colon carcinomas, Hath1 was up-regulated in 7 out of 10 tumors upon DBZ treatment. Parallel MUC2 up-regulation occurred in 4 (4/7) and P27kip1 in only 2 (2/7) tumors. Interestingly, the response patterns of primary tumors to DBZ fitted with the hierarchical model of divergent signalling derived from our findings on cell lines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid Precursor Protein Secretases / antagonists & inhibitors*
  • Basic Helix-Loop-Helix Transcription Factors / genetics*
  • Basic Helix-Loop-Helix Transcription Factors / metabolism
  • Carcinoma / genetics*
  • Carcinoma / metabolism
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cell Survival / genetics
  • Colonic Neoplasms / genetics*
  • Colonic Neoplasms / metabolism
  • Cyclin-Dependent Kinase Inhibitor p27 / genetics*
  • Cyclin-Dependent Kinase Inhibitor p27 / metabolism
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation, Neoplastic / drug effects
  • Goblet Cells / drug effects
  • Goblet Cells / metabolism
  • Humans
  • Models, Biological
  • Mucin-2 / genetics*
  • Mucin-2 / metabolism
  • RNA Interference
  • Signal Transduction / drug effects
  • Translational Research, Biomedical
  • Tumor Cells, Cultured

Substances

  • ATOH1 protein, human
  • Basic Helix-Loop-Helix Transcription Factors
  • Enzyme Inhibitors
  • Mucin-2
  • Cyclin-Dependent Kinase Inhibitor p27
  • Amyloid Precursor Protein Secretases

Grants and funding

This work was supported in part by “Ligue Départementale contre le cancer de Loire-Atlantique”, and GEFLUC (Groupement des Entreprises Françaises dans la Lutte contre le Cancer). CK is a recipient of a predoctoral fellowship from the Fédération Hospitalière de France. FS is recipient of a tenure position supported by the Institut National de la Santé et de la Recherche Médicale (INSERM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.